Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rhea: TP-03 Vehicle in MGD
NCT06054217Phase 2Active, not recruiting
- Sponsor
- Tarsus Pharmaceuticals, Inc.
- Start
- Aug 2023
- Primary completion
- Jun 2024
- Modality
- Placebo
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TP-03 vehicle in meibomian gland dysfunction (MGD) (3 cohorts), sponsored by Tarsus Pharmaceuticals, Inc. Primary endpoint: Treatment Emergent Adverse Events at 85 days. Started Aug 2023; status: active, not recruiting.
02
Drugs
TP-03 vehicle
03
Conditions
meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on NCT06054217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06054217.